Can galeterone show effectiveness in men with AR-V7 mCRPC?

According to a report in The ASCO Post last night, the investigational drug galeterone may have significant clinical activity against a specific subtype of castration-resistant prostate cancer (CRPC) known as AR-V7. … READ MORE …

Combination immunotherapy for men with mCRPC: another new trial proposed

Late yesterday, Advaxis Immunotherapies announced the potential initiation of human trials of another new form of immunotherapy for the treatment of metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Does olaparib have real potential in treatment of mCRPC?

According to a report on the Reuters web site yesterday, some researchers are of the opinion that the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib (recently recommended for approval in Europe for the treatment of a subset of women with ovarian cancer) may be valuable in the treatment of some forms of prostate cancer too. … READ MORE …

Evolution of the mCRPC treatment landscape

A new article by Jeffress in the cancer business publication OBR Green discusses the changing patterns of use of  the various approved drugs in the treatment of metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

KPT-330 in treatment of mCRPC

Earlier this year, Karyopharm Therapeutics initiated a Phase II clinical trial of KPT-330 in treatment of men with metastatic, castration-resistant prostate cancer (mCRPC) who had progressed on treatment with drugs like abiraterone acetate and enzalutamide. … READ MORE …

“Final” data on abiraterone acetate in treatment of chemo-naive mCRPC

According to a media release issued on Sunday, the most recent “final” update to the COU-AA-302 trial has shown that treatment with abiraterone + prednisone provided a statistically significant overall survival benefit in the treatment of men with chemotherapy-naive, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Data from early access trial of abiraterone acetate in post-chemo mCRPC

A new article in The Lancet Oncology has provided us with data from the early access trial of abiraterone acetate + predisone conducted in men with post-chemotherapy, metastatic, castration-resistant prostate cancer (mCRPC) in a total of 23 countries around the world. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,173 other followers